Such manipulation of whole tumour cell lysates leads to the exposure of phosphatidylserine (PS) on the tumour cell surface and to the release of apoptotic mediators (high mobility group box 1-HMGB1, calreticulin-CRT and pentraxin-3-PTX3), thus enhancing DC stimulation and capture capacity and resulting in the reversal of cancer-immunity cycle events [190, 192–194]. The gene discussed is PTX3; the disease is cancer.